Anti-Aging Drug Discovery Targeting BCL-XL

B-cell lymphoma-extra large (BCL-XL) is an anti-apoptotic protein that promotes cell survival by inhibiting the intrinsic apoptotic pathway. As organisms age, the dysregulation of apoptosis can lead to several age-related diseases, including neurodegenerative diseases, cardiovascular diseases, and cancers. Research indicates that BCL-XL expression levels decline with age, which may contribute to increased cellular senescence and loss of tissue homeostasis. However, increasing BCL-XL activity can extend cellular lifespan and improve tissue function.

Fig. 1 BCL-XL modulation of senescence. (Mas-Bargues C, et al., 2021)

At CD BioSciences, we prioritize the identification of key molecular targets that have the potential to reverse age-related changes and promote healthy aging. We offer a range of services to help clients discover and develop anti-aging drugs that specifically target BCL-XL.

How Do We Identify BCL-XL as an Anti-Aging Target?

Extensive research has demonstrated BCL-XL overexpression in aging tissues and its association with extended lifespan when genetically modulated. Identifying BCL-XL as a target for anti-aging drugs requires a systematic and multifaceted approach. We utilize bioinformatics tools to map signaling pathways involving BCL-XL and help clients identify upstream regulators and downstream effects on cellular processes. To investigate the role of BCL-XL in aging, we also employ various cellular models to study their natural behavior and response to BCL-XL modulation.

How Do We Develop Anti-Aging Drugs Targeting BCL-XL?

Leveraging our expertise in molecular biology and pharmacology, CD BioSciences helps clients accelerate the development of innovative anti-aging drugs targeting BCL-XL.

• Drug screening. Utilizing high-throughput screening, our research team helps clients develop drugs that specifically target BCL-XL. We help clients discover drugs that mimic the binding of pro-apoptotic proteins to BCL-XL, thereby promoting apoptosis in senescent cells.
• In vitro and in vivo validation. We rigorously test drugs targeting BCL-XL in vitro using cell-based assays that measure apoptosis and senescence. Additionally, we use in vivo models of aging and age-related diseases to assess the efficacy and safety of these drug candidates.
• Mechanistic analysis. We also help clients conduct in-depth analyses of how drugs targeting BCL-XL affect aging-related pathways, including apoptosis, autophagy, and inflammation.

Targeting BCL-XL in Age-Related Macular Degeneration

Age-related macular degeneration (AMD), a leading cause of vision loss in the elderly, is associated with dysregulated apoptosis in retinal cells. CD BioSciences is actively exploring the role of drugs targeting BCL-XL in mitigating the effects of AMD, employing our extensive knowledge of drug formulation and ocular pharmacology. We also help clients analyze the potential of these drugs to preserve cell function and prevent degeneration by inhibiting apoptosis in retinal pigment epithelial (RPE) cells, thereby protecting vision.

Targeting BCL-XL holds significant promise in the realm of anti-aging drug discovery. CD BioSciences is committed to providing innovative approaches and comprehensive services to advance this research. If you are interested in our services, please feel free to contact us or make an online inquiry.

Reference

1. Mas-Bargues C, et al. BCL-XL as a Modulator of Senescence and Aging. Int J Mol Sci, 2021, 22 (4): 1527.